Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corp. notice of proposed resale of 10,000 shares of Common Stock by Fidelity Brokerage Services LLC under Rule 144. The filing lists recent open‑market dispositions by Alex R. Thurman totaling 4,657 shares across March 17, 24 and 25, 2026, with cash proceeds reported for each trade.
Glaukos Corporation reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $150.6 million from $106.7 million a year earlier, driven mainly by higher U.S. glaucoma revenue from the iDose TR sustained-release implant and growth in international glaucoma procedures.
Corneal health revenue also increased as Photrexa and the early Epioxa launch contributed more U.S. sales. Gross margin was 78%, similar to last year, but higher selling, general and administrative expenses of $92.9 million and research and development spending of $44.1 million kept the company in the red, with a net loss of $19.8 million, or $0.34 per share.
Glaukos ended the quarter with $280.5 million in cash, cash equivalents, short-term investments and restricted cash. The company highlighted an option agreement for potential new drug technology and noted a permanent HCPCS J-code for Epioxa effective July 2026, which is expected to simplify U.S. reimbursement for its new keratoconus therapy.
Glaukos Corp reported that Vanguard Capital Management beneficially owns 2,947,047 shares of Common Stock, representing 5.07% of the class. The filing states Vanguard has sole dispositive power over 2,947,047 shares and sole voting power for 438,276 shares.
The Schedule 13G notes these holdings include securities held for Vanguard funds and managed accounts; the filing is signed by Vanguard's Head of Global Fund Administration.
Glaukos Corporation reported strong first quarter 2026 growth but remains unprofitable. Net sales reached $150.6 million, up 41% year-over-year, driven mainly by glaucoma products, including U.S. Glaucoma revenue of $93.5 million and growing adoption of the iDose TR therapy.
GAAP gross margin was about 78%, with non-GAAP gross margin near 84%. The company posted a GAAP net loss of $19.8 million, or ($0.34) per share, and a non-GAAP net loss of $10.4 million, or ($0.18) per share. Glaukos ended the quarter with $280.5 million in cash, equivalents, short-term investments and restricted cash and no debt, and raised its 2026 net sales guidance to $620–$635 million.
Vanguard Portfolio Management reports beneficial ownership of 3,256,962 shares of Glaukos Corp common stock, representing 5.6% of the class as of 03/31/2026. The filer discloses sole dispositive power over 3,256,962 shares and sole voting power for 48,599 shares. The statement was filed as a Schedule 13G and signed on 04/29/2026.
Glaukos Corporation has issued its 2026 proxy statement for the May 28, 2026 virtual annual meeting, asking stockholders to elect two Class II directors, approve executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor.
For 2025, Glaukos reports net sales of $507 million and cash, equivalents, restricted cash and short-term investments of $283 million as of December 31, 2025. The eight‑member board is 88% independent, 38% women, and 25% from underrepresented communities, with an average age of 60.6 years and average tenure of 12.6 years.
The proxy highlights say‑on‑pay support of 97.7% at the 2025 meeting, a pay program emphasizing variable, performance‑linked compensation, stock ownership and clawback policies, and strong governance practices including overboarding limits, an updated code of conduct, active cybersecurity oversight, and expanding sustainability and climate initiatives.
Glaukos Corp’s chief development officer, Tomas Navratil, sold 2,093 shares of common stock in open‑market trades. The sales on April 10, 2026 were executed at prices ranging from about $116.72 to $120.23 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 12, 2026.
After these transactions, Navratil directly holds 90,370 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered. The filing notes that several trades were executed in multiple lots, with the reported prices reflecting weighted averages.
Glaukos Corporation submitted a Form 144 notice disclosing proposed sales of Common Stock by an affiliate through broker Fidelity Brokerage Services LLC. The filing lists past sales of 1,031 shares on 03/16/2026 for $101,085.67 and identifies restricted stock vesting events of 338, 517, and 1,238 shares on 12/13/2024, 12/18/2024, and 01/01/2025, respectively.
Glaukos Corp’s Chief Development Officer Tomas Navratil reported a routine tax-withholding disposition of 2,977 shares of common stock. The issuer withheld 1,146 shares and 1,831 shares at $109.60 per share to cover tax obligations upon vesting and delivery of restricted stock units granted in 2022 and 2024.
After these withholdings, Navratil directly owns 92,463 shares of common stock. His position also reflects 43,483 restricted stock units from the March 24, 2022 grant and 39,791 restricted stock units from the March 14, 2024 grant that have not yet vested or been delivered.